MSMP (microseminoprotein, prostate-associated) is a chemokine that functions as a ligand for the C-C chemokine receptor CCR2, inducing strong chemotactic responses and intracellular calcium mobilization. It selectively recruits monocytes and lymphocytes but not neutrophils through CCR2 binding and activation. In hepatic fibrosis, MSMP expression is elevated in fibrotic tissues and drives disease progression by promoting inflammatory macrophage infiltration and hepatic stellate cell activation via the CCR2/PI3K/AKT signaling pathway 1. Similarly, MSMP promotes acute kidney injury by recruiting CCR2-expressing pro-inflammatory macrophages and driving M1 polarization 2. In cancer, hypoxia-induced MSMP secretion from tumor cells triggers endothelial cell signaling to promote angiogenesis and anti-VEGF therapy resistance; serum MSMP levels increase specifically in patients who do not respond to bevacizumab 3. Therapeutically, MSMP inhibition shows promise across multiple disease contexts. MSMP-neutralizing antibodies prevent liver fibrosis development in murine models 1 and reduce acute kidney injury in vivo 2. A traditional Chinese medicine formula reduces hepatic fibrosis by suppressing MSMP expression and its downstream CCR2 signaling 4. These findings identify MSMP as a potential therapeutic target across fibrotic, inflammatory, and cancer-related pathologies.